Table 2.

Effects of various inhibitors on the TF-induced clotting time in human plasma

Inhibitor	[Inhibitor]1.5 × CT,*nM	Relative potency†
TAP-ANV	0.80	86
ANV 6L15	6.0	12
ANV-KAPP	9.4	7.3
ANV-KKTFPI	11	6.3
ANV	29	2.4
TAP	68	1
TFPI	69	1
E. coli TFPI1-160	2750	0.025
6L15	5900	0.012

Pooled human plasma (100 μL) was mixed with an equal volume of an inhibitor dissolved in buffer (10 mM Tris, pH 7.4; 0.15 M NaCl; 1 mg/mL BSA; 0.02% NaN₃) at varying concentrations. Dade Innovin was diluted 1:100 with buffer (75 mM NaCl, 12.5 mM CaCl₂, 0.5 mg/mL BSA, 0.02% NaN₃) for the assay. Clotting times were determined with an ACL 200 coagulation analyzer.

^*Concentration of inhibitor that prolongs the TF-induced clotting time 1.5-fold relative to control (ie, from 40.7 to 61.1 seconds)

^†Calculated by dividing [Inhibitor]_{1.5 × CT} for TFPI by the value for the other specified inhibitor